The purpose of this study is to determine whether rosuvastatin is effective as a coadjuvant drug in the integral management of abdominal sepsis acknowledged by surgery.
The sepsis is often lethal, the mortality's ranks are identified among 25 to 70%, this depends on definition, severity and co-morbidities. The number of deaths by sepsis could be similar to myocardial infarct. Patients who get shock have 26-fold risk of death. In preliminary studies have been observed, that patients with treatment with statin have minor incidence of severe sepsis. A retrospective study suggests the association between using statins and reduction of bacteriemia by Gram negatives and S. aureus. There are many experimental studies which demonstrate the possible profit in sepsis. However there are no clinical prospective studies for determinate if statins are effective in management of sepsis. The investigators designed this study to demonstrate the utility of rosuvastatin in one kind of sepsis, abdominal sepsis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
60
20 mg 10 days daily since abdominal sepsis diagnosis
Hospital Central "Dr. Ignacio Morones Prieto
San Luis Potosí City, San Luis Potosí, Mexico
RECRUITINGPlasmatic levels of Interleukine 6 and 1B, and Tumor Necrosis Factor alpha (pg/dL)
Time frame: day 3
Number of survivors
in-patient follow-up will be considered as well
Time frame: 1 week after randomization
Plasmatic levels of Reactive C Protein (mg/dL)
Time frame: day 3
Classification of severity by APACHE II scale
Time frame: day 3
Incidence of complications or secondary effects
Time frame: day 1, 3, 7, 14 after randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.